Evidence map›Paper›PMID 29976202›Full record

ArticleCell communication and signaling : CCS2018

The exon 19-deleted EGFR undergoes ubiquitylation-mediated endocytic degradation via dynamin activity-dependent and -independent mechanisms.

Taishu Wang, Jinrui Zhang, Shanshan Wang, Xiuna Sun, Duchuang Wang, Yurou Gao, Yang Zhang, Lu Xu, Yue Wu, Yueguang Wu and 7 more

Open access · goldAbstract read
In one paragraph

Article in Cell communication and signaling : CCS, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers.

0numbers the graph read from it
0cells of the map it votes in
16citing papers in PubMed
1.8field-weighted citation impact, top 15% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

16 citing papers in PubMed, 23 citations in OpenAlex.

  1. Article
  2. Article
  3. A CMTM6 Nanobody Overcomes EGFR-TKI Resistance in Non-Small Cell Lung Cancer.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2025
    Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Article
  13. Article
  14. Article
  15. Article
  16. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

17 authors at 1 institution in 1 country.

Taishu WangThe Second Affiliated Hospital, Institute of Cancer Stem Cell, Dalian Medical University, Dalian, China.
Jinrui ZhangThe Second Affiliated Hospital, Institute of Cancer Stem Cell, Dalian Medical University, Dalian, China.
Shanshan WangThe Second Affiliated Hospital, Institute of Cancer Stem Cell, Dalian Medical University, Dalian, China.
Xiuna SunDepartment of Respiratory Medicine, First Affiliated Hospital, Dalian Medical University, Dalian, China.
Duchuang WangThe Second Affiliated Hospital, Institute of Cancer Stem Cell, Dalian Medical University, Dalian, China.
Yurou GaoThe Second Affiliated Hospital, Institute of Cancer Stem Cell, Dalian Medical University, Dalian, China.
Yang ZhangThe Second Affiliated Hospital, Institute of Cancer Stem Cell, Dalian Medical University, Dalian, China.
Lu XuThe Second Affiliated Hospital, Institute of Cancer Stem Cell, Dalian Medical University, Dalian, China.
Yue WuThe Second Affiliated Hospital, Institute of Cancer Stem Cell, Dalian Medical University, Dalian, China.
Yueguang WuThe Second Affiliated Hospital, Institute of Cancer Stem Cell, Dalian Medical University, Dalian, China.
Fang LiuThe Second Affiliated Hospital, Institute of Cancer Stem Cell, Dalian Medical University, Dalian, China.
Xiuxiu LiuThe Second Affiliated Hospital, Institute of Cancer Stem Cell, Dalian Medical University, Dalian, China.
Shuyan LiuThe Second Affiliated Hospital, Institute of Cancer Stem Cell, Dalian Medical University, Dalian, China.
Yingqiu ZhangThe Second Affiliated Hospital, Institute of Cancer Stem Cell, Dalian Medical University, Dalian, China.
Yang WangThe Second Affiliated Hospital, Institute of Cancer Stem Cell, Dalian Medical University, Dalian, China.
Lijuan ZouThe Second Affiliated Hospital, Institute of Cancer Stem Cell, Dalian Medical University, Dalian, China. zoulijuan1963@sina.com.
Han LiuThe Second Affiliated Hospital, Institute of Cancer Stem Cell, Dalian Medical University, Dalian, China. liuhan@dlmedu.edu.cn.ORCID 0000-0002-0014-4675
Dalian Medical University · CN

Funding

National Natural Science Foundation of China 81301901National Natural Science Foundation of China 81473452
6 · The paper itself

Abstract

backgroundThe epidermal growth factor receptor (EGFR) is closely implicated in cancer, and sequencing analyses have revealed a high mutation rate of EGFR in lung cancer. Recent advances have provided novel insights into the endocytic regulation of wild-type EGFR, but that of mutated EGFR remains elusive. In the present study, we aim to investigate the endocytic degradation of a frequently occurred exon 19-deleted mutant in lung cancer.

methodsThe EGF-induced endocytic degradation of EGFR was examined in a panel of lung cancer cells using immunoblotting. The subcellular distribution of internalized EGFR was investigated using immunofluorescence and confocal microscopy. The effects of dynamin were assessed using its small molecule inhibitors, while the influence of RTN3 was tested using shRNA-mediated knockdown. Finally the ubiquitylation status of EGFR mutant was studied using immunoprecipitation under steady state and tyrosine kinase inhibitor-treated conditions.

resultsEGF induced various rates of EGFR endocytic degradation in lung cancer cells. Interestingly, the exon 19 deletion mutant is constantly internalized and sorted to lysosome for degradation, and this process is independent of dynamin activity. EGF stimulation and HSP90 inhibition further enhance the endocytic degradation of the exon 19 deletion mutant, in a dynamin activity-dependent and -independent manner, respectively. Albeit with different modes of internalization, the uptake of the exon 19-deleted EGFR is mediated through receptor ubiquitylation.

conclusionsThe internalized EGFR mutant is constantly routed through endosome to lysosome for degradation. The endocytosis of EGFR mutant occurs through both dynamin activity-dependent and -independent mechanisms. Our findings gain novel insights into the endocytic regulation of mutated EGFR and may have potential clinical implications.

Indexed as

Sequence DeletionCell Line, TumorDynaminsEndocytosisErbB ReceptorsExonsHumansLung NeoplasmsProtein TransportProteolysisUbiquitinationDynaminsErbB ReceptorsEGFREndocytosisExon 19 deletionNSCLCUbiquitylation

Identifiers

PMID29976202
PMCPMC6034242
OpenAlexW2823592088

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.